MX379292B - Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas. - Google Patents
Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas.Info
- Publication number
- MX379292B MX379292B MX2015013175A MX2015013175A MX379292B MX 379292 B MX379292 B MX 379292B MX 2015013175 A MX2015013175 A MX 2015013175A MX 2015013175 A MX2015013175 A MX 2015013175A MX 379292 B MX379292 B MX 379292B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hyperproliferative diseases
- treatment
- coumarin derivatives
- fibrosis
- Prior art date
Links
- 150000001893 coumarin derivatives Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788398P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027154 WO2014152278A2 (en) | 2013-03-15 | 2014-03-14 | Coumarin derivatives and methods of use in treating hyperproliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013175A MX2015013175A (es) | 2016-04-04 |
| MX379292B true MX379292B (es) | 2025-03-11 |
Family
ID=51581693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013175A MX379292B (es) | 2013-03-15 | 2014-03-14 | Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10369145B2 (enExample) |
| EP (1) | EP2970249A4 (enExample) |
| JP (1) | JP6407955B2 (enExample) |
| KR (1) | KR20150132483A (enExample) |
| CN (1) | CN105246887B (enExample) |
| AU (1) | AU2014240003B2 (enExample) |
| CA (1) | CA2903107C (enExample) |
| HK (1) | HK1218537A1 (enExample) |
| MX (1) | MX379292B (enExample) |
| WO (1) | WO2014152278A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2836463A1 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
| AU2013348019A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic CFTR correctors |
| EP2922852A4 (en) | 2012-11-20 | 2016-05-25 | Discoverybiomed Inc | SMALL MOLECULAR CFTR CORRECTORS |
| KR20150131309A (ko) | 2013-03-15 | 2015-11-24 | 디스커버리바이오메드 인코포레이티드 | 쿠마린 유도체 및 낭포성 섬유증, 만성 폐쇄성 폐 질환 및 미스폴딩된 단백질 장애의 치료에서의 사용 방법 |
| KR20150132483A (ko) | 2013-03-15 | 2015-11-25 | 디스커버리바이오메드 인코포레이티드 | 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법 |
| CN105541852B (zh) * | 2016-01-29 | 2017-09-15 | 扬州大学 | 2‑（香豆素‑3‑基）‑6‑甲基吡啶并[5,4‑c]香豆素的合成方法 |
| CN107098895B (zh) * | 2016-02-19 | 2020-01-07 | 湖南大学 | 苯氨基噻唑甲基喹啉酮衍生物及其制备方法与应用 |
| US20200289482A1 (en) * | 2017-06-21 | 2020-09-17 | The Johns Hopkins University | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease |
| CN109464440A (zh) * | 2019-01-17 | 2019-03-15 | 北京大学 | 3-乙酰氨基香豆素在制备治疗或预防肾脏纤维化及慢性肾病的药物中的应用 |
| CN112274517A (zh) * | 2020-10-30 | 2021-01-29 | 江苏大学 | 一种治疗套细胞淋巴瘤的药物组合物 |
| KR20250109620A (ko) * | 2024-01-09 | 2025-07-17 | 주식회사 프로티나 | 신규 화합물 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5566580A (en) | 1978-11-11 | 1980-05-20 | Kaken Pharmaceut Co Ltd | Coumarin derivative, its preparation and antiallergic agent containing the same as effective component |
| US20030055263A1 (en) | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
| DE10133665A1 (de) | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| US20060122387A1 (en) | 2002-06-13 | 2006-06-08 | Cti Europe S.R.L. | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| EP2939674A1 (en) * | 2004-10-13 | 2015-11-04 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| CN101076332A (zh) | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途 |
| WO2006044457A1 (en) | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| US20090012148A1 (en) | 2005-11-01 | 2009-01-08 | Maxfield Frederick R | Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis |
| CN101351208A (zh) | 2005-11-01 | 2009-01-21 | 康乃尔研究基金会有限公司 | 减少细胞胆固醇水平和/或治疗或预防磷脂质病 |
| WO2009076665A1 (en) | 2007-12-13 | 2009-06-18 | Indiana University Research And Technology Corporation | Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase |
| WO2010111713A2 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
| ITMI20111068A1 (it) | 2011-06-14 | 2012-12-15 | Azienda Ospedaliera Universitaria I Ntegrata Di Ve | Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale |
| KR20150132483A (ko) | 2013-03-15 | 2015-11-25 | 디스커버리바이오메드 인코포레이티드 | 쿠마린 유도체 및 과증식성 질환의 치료에서의 사용 방법 |
| KR20150131309A (ko) | 2013-03-15 | 2015-11-24 | 디스커버리바이오메드 인코포레이티드 | 쿠마린 유도체 및 낭포성 섬유증, 만성 폐쇄성 폐 질환 및 미스폴딩된 단백질 장애의 치료에서의 사용 방법 |
-
2014
- 2014-03-14 KR KR1020157029644A patent/KR20150132483A/ko not_active Ceased
- 2014-03-14 AU AU2014240003A patent/AU2014240003B2/en not_active Ceased
- 2014-03-14 CN CN201480015013.4A patent/CN105246887B/zh not_active Expired - Fee Related
- 2014-03-14 JP JP2016502351A patent/JP6407955B2/ja not_active Expired - Fee Related
- 2014-03-14 HK HK16106496.8A patent/HK1218537A1/zh unknown
- 2014-03-14 US US14/775,050 patent/US10369145B2/en active Active
- 2014-03-14 EP EP14768111.8A patent/EP2970249A4/en not_active Withdrawn
- 2014-03-14 CA CA2903107A patent/CA2903107C/en active Active
- 2014-03-14 WO PCT/US2014/027154 patent/WO2014152278A2/en not_active Ceased
- 2014-03-14 MX MX2015013175A patent/MX379292B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014152278A3 (en) | 2014-11-13 |
| EP2970249A2 (en) | 2016-01-20 |
| WO2014152278A2 (en) | 2014-09-25 |
| JP2016513685A (ja) | 2016-05-16 |
| EP2970249A4 (en) | 2017-03-15 |
| US10369145B2 (en) | 2019-08-06 |
| CN105246887A (zh) | 2016-01-13 |
| CN105246887B (zh) | 2018-05-11 |
| US20160038475A1 (en) | 2016-02-11 |
| CA2903107C (en) | 2021-11-02 |
| CA2903107A1 (en) | 2014-09-25 |
| AU2014240003B2 (en) | 2017-12-14 |
| AU2014240003A1 (en) | 2015-09-03 |
| JP6407955B2 (ja) | 2018-10-17 |
| HK1218537A1 (zh) | 2017-02-24 |
| MX2015013175A (es) | 2016-04-04 |
| KR20150132483A (ko) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379292B (es) | Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas. | |
| UY39630A (es) | Inhibidores de bromodominios | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| BR112015022191A8 (pt) | compostos heteroarila e usos dos mesmos | |
| CR20160035A (es) | Inhibidores de bromodominios | |
| NI201300041A (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| PE20151023A1 (es) | Triazolopirazinas | |
| MX346730B (es) | Composiciones y metodos para el tratamiento de la hipertension pulmonar. | |
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| AR097931A1 (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| EA201591499A1 (ru) | Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза) | |
| EA201892726A1 (ru) | Дейтерированный палбоциклиб | |
| CY1118371T1 (el) | Αναστολεις του iap | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| NI201300034A (es) | Conjugado de naloxol - peg cristalino |